17beta-estradiol multiple interactions ISO RGD:1349867 6480464 [Estradiol co-treated with TGFB1 protein] results in decreased expression of GPM6B mRNA CTD PMID:30165855 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1349867 6480464 Dihydrotestosterone results in increased expression of GPM6B mRNA CTD PMID:29581250 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1349867 6480464 Tetrachlorodibenzodioxin results in decreased expression of GPM6B mRNA CTD PMID:20106945 3,3',4,4',5-pentachlorobiphenyl decreases expression ISO RGD:620580 6480464 3 more ... CTD PMID:23196670 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1349867 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of GPM6B mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane decreases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of GPM6B mRNA CTD PMID:18648102 4-hydroxyphenyl retinamide decreases expression EXP 6480464 Fenretinide results in decreased expression of GPM6B mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine affects expression ISO RGD:1349867 6480464 Decitabine affects the expression of GPM6B mRNA CTD PMID:23300844 6alpha-methylprednisolone increases expression ISO RGD:1349867 6480464 Methylprednisolone results in increased expression of GPM6B mRNA CTD PMID:19192274 aflatoxin B1 affects expression ISO RGD:1349867 6480464 Aflatoxin B1 affects the expression of GPM6B protein CTD PMID:20106945 aflatoxin B1 increases methylation ISO RGD:1349867 6480464 Aflatoxin B1 results in increased methylation of GPM6B intron CTD PMID:30157460 aflatoxin B1 decreases methylation ISO RGD:1349867 6480464 Aflatoxin B1 results in decreased methylation of GPM6B gene CTD PMID:27153756 aflatoxin B2 increases methylation ISO RGD:1349867 6480464 aflatoxin B2 results in increased methylation of GPM6B intron CTD PMID:30157460 all-trans-retinoic acid decreases expression ISO RGD:1349867 6480464 Tretinoin results in decreased expression of GPM6B mRNA CTD PMID:21934132 ammonium chloride affects expression ISO RGD:620580 6480464 Ammonium Chloride affects the expression of GPM6B mRNA CTD PMID:16483693 arsenous acid decreases expression ISO RGD:1349867 6480464 Arsenic Trioxide results in decreased expression of GPM6B mRNA CTD PMID:26705709 astemizole increases expression ISO RGD:620580 6480464 Astemizole results in increased expression of GPM6B mRNA CTD PMID:20221588 azathioprine increases expression ISO RGD:1349867 6480464 Azathioprine results in increased expression of GPM6B mRNA CTD PMID:19192274 benzo[a]pyrene affects methylation ISO RGD:1349867 6480464 Benzoapyrene affects the methylation of GPM6B exon, Benzoapyrene affects the methylation of GPM6B intron CTD PMID:27901495 , PMID:30157460 benzo[a]pyrene increases expression ISO RGD:1349867 6480464 Benzoapyrene results in increased expression of GPM6B mRNA CTD PMID:32234424 benzo[a]pyrene increases methylation ISO RGD:1349867 6480464 Benzoapyrene results in increased methylation of GPM6B promoter CTD PMID:27901495 benzo[e]pyrene increases methylation ISO RGD:1349867 6480464 benzoepyrene results in increased methylation of GPM6B intron CTD PMID:30157460 beta-naphthoflavone multiple interactions ISO RGD:620580 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GPM6B mRNA CTD PMID:18164116 bexarotene increases expression ISO RGD:1349867 6480464 bexarotene results in increased expression of GPM6B mRNA CTD PMID:17178900 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1349867 6480464 Diethylhexyl Phthalate results in increased expression of GPM6B protein CTD PMID:31163220 bisphenol A increases expression ISO RGD:620580 6480464 bisphenol A results in increased expression of GPM6B mRNA CTD PMID:18180321 bisphenol A decreases expression ISO RGD:620580 6480464 bisphenol A results in decreased expression of GPM6B mRNA CTD PMID:30816183 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of GPM6B mRNA CTD PMID:25594700 bisphenol F increases expression EXP 6480464 bisphenol F results in increased expression of GPM6B mRNA CTD PMID:30951980 butanal increases expression ISO RGD:1349867 6480464 butyraldehyde results in increased expression of GPM6B mRNA CTD PMID:26079696 choline multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GPM6B mRNA CTD PMID:20938992 chromium(6+) increases expression ISO RGD:1349867 6480464 chromium hexavalent ion results in increased expression of GPM6B mRNA CTD PMID:17382205 cisplatin affects expression ISO RGD:1349867 6480464 Cisplatin affects the expression of GPM6B mRNA CTD PMID:23300844 cocaine decreases expression ISO RGD:1349867 6480464 Cocaine results in decreased expression of GPM6B mRNA CTD PMID:12629581 copper atom multiple interactions ISO RGD:1349867 6480464 [NSC 689534 binds to Copper] which results in decreased expression of GPM6B mRNA CTD PMID:20971185 copper(0) multiple interactions ISO RGD:1349867 6480464 [NSC 689534 binds to Copper] which results in decreased expression of GPM6B mRNA CTD PMID:20971185 cyclosporin A decreases expression ISO RGD:1349867 6480464 Cyclosporine results in decreased expression of GPM6B mRNA CTD PMID:20106945 decabromodiphenyl ether decreases expression ISO RGD:620580 6480464 decabromobiphenyl ether results in decreased expression of GPM6B mRNA CTD PMID:23640034 dexamethasone multiple interactions ISO RGD:1349867 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of GPM6B mRNA CTD PMID:28628672 diarsenic trioxide decreases expression ISO RGD:1349867 6480464 Arsenic Trioxide results in decreased expression of GPM6B mRNA CTD PMID:26705709 dorsomorphin multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 entinostat multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of GPM6B mRNA CTD PMID:27188386 entinostat increases expression ISO RGD:1349867 6480464 entinostat results in increased expression of GPM6B mRNA CTD PMID:26272509 ethanol affects splicing EXP 6480464 Ethanol affects the splicing of GPM6B mRNA CTD PMID:30319688 ethanol increases expression EXP 6480464 Ethanol results in increased expression of GPM6B mRNA CTD PMID:30319688 etoposide affects response to substance ISO RGD:1349867 6480464 GPM6B protein affects the susceptibility to Etoposide CTD PMID:16217747 folic acid multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GPM6B mRNA CTD PMID:20938992 furan increases expression ISO RGD:620580 6480464 furan results in increased expression of GPM6B mRNA CTD PMID:27387713 genistein decreases expression EXP 6480464 Genistein results in decreased expression of GPM6B mRNA CTD PMID:32186404 glycidol decreases expression ISO RGD:620580 6480464 glycidol results in decreased expression of GPM6B mRNA CTD PMID:24915197 indometacin multiple interactions ISO RGD:1349867 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of GPM6B mRNA CTD PMID:28628672 L-methionine multiple interactions EXP 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of GPM6B mRNA CTD PMID:20938992 lead(0) affects splicing ISO RGD:1349867 6480464 Lead affects the splicing of GPM6B mRNA CTD PMID:28903495 lead(0) affects expression ISO RGD:1349867 6480464 Lead affects the expression of GPM6B mRNA CTD PMID:28903495 lead(2+) affects splicing ISO RGD:1349867 6480464 Lead affects the splicing of GPM6B mRNA CTD PMID:28903495 lead(2+) affects expression ISO RGD:1349867 6480464 Lead affects the expression of GPM6B mRNA CTD PMID:28903495 mercury dibromide decreases expression ISO RGD:1349867 6480464 mercuric bromide results in decreased expression of GPM6B mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of GPM6B mRNA CTD PMID:27188386 methapyrilene increases methylation ISO RGD:1349867 6480464 Methapyrilene results in increased methylation of GPM6B intron CTD PMID:30157460 methotrexate increases expression ISO RGD:1349867 6480464 Methotrexate results in increased expression of GPM6B mRNA CTD PMID:19192274 methyl methanesulfonate decreases expression ISO RGD:1349867 6480464 Methyl Methanesulfonate results in decreased expression of GPM6B mRNA CTD PMID:23649840 miconazole decreases expression EXP 6480464 Miconazole results in decreased expression of GPM6B mRNA CTD PMID:27462272 N-nitrosodiethylamine multiple interactions ISO RGD:620580 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of GPM6B mRNA CTD PMID:18164116 nickel sulfate increases expression ISO RGD:1349867 6480464 nickel sulfate results in increased expression of GPM6B mRNA CTD PMID:17382205 oxaliplatin multiple interactions ISO RGD:620580 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of GPM6B mRNA CTD PMID:25729387 oxaliplatin increases expression ISO RGD:620580 6480464 oxaliplatin results in increased expression of GPM6B mRNA CTD PMID:25729387 p-chloromercuribenzoic acid decreases expression ISO RGD:1349867 6480464 p-Chloromercuribenzoic Acid results in decreased expression of GPM6B mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of GPM6B mRNA CTD PMID:27188386 paracetamol decreases expression ISO RGD:1349867 6480464 Acetaminophen results in decreased expression of GPM6B mRNA CTD PMID:29067470 phenobarbital affects expression ISO RGD:1349867 6480464 Phenobarbital affects the expression of GPM6B mRNA CTD PMID:19159669 phenylmercury acetate decreases expression ISO RGD:1349867 6480464 Phenylmercuric Acetate results in decreased expression of GPM6B mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of GPM6B mRNA CTD PMID:27188386 potassium chromate increases expression ISO RGD:1349867 6480464 potassium chromateVI results in increased expression of GPM6B mRNA CTD PMID:17382205 prednisolone increases expression ISO RGD:1349867 6480464 Prednisolone results in increased expression of GPM6B mRNA CTD PMID:19192274 SB 431542 multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 silver atom decreases expression EXP 6480464 Silver results in decreased expression of GPM6B mRNA CTD PMID:27131904 silver(0) decreases expression EXP 6480464 Silver results in decreased expression of GPM6B mRNA CTD PMID:27131904 sodium arsenate increases expression EXP 6480464 sodium arsenate results in increased expression of GPM6B mRNA CTD PMID:21795629 sodium aurothiomalate increases expression ISO RGD:1349867 6480464 Gold Sodium Thiomalate results in increased expression of GPM6B mRNA CTD PMID:19192274 sulforaphane decreases expression ISO RGD:1349867 6480464 sulforafan results in decreased expression of GPM6B mRNA CTD PMID:31838189 testosterone enanthate affects expression ISO RGD:1349867 6480464 testosterone enanthate affects the expression of GPM6B mRNA CTD PMID:17440010 topotecan increases expression ISO RGD:620580 6480464 Topotecan results in increased expression of GPM6B mRNA CTD PMID:25729387 topotecan multiple interactions ISO RGD:620580 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of GPM6B mRNA CTD PMID:25729387 trichostatin A increases expression ISO RGD:1349867 6480464 trichostatin A results in increased expression of GPM6B mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of GPM6B mRNA CTD PMID:27188386 triclosan decreases expression ISO RGD:1349867 6480464 Triclosan results in decreased expression of GPM6B mRNA CTD PMID:30510588 tunicamycin decreases expression ISO RGD:1349867 6480464 Tunicamycin results in decreased expression of GPM6B mRNA CTD PMID:22378314 valproic acid decreases methylation ISO RGD:1349867 6480464 Valproic Acid results in decreased methylation of GPM6B gene CTD PMID:29154799 valproic acid multiple interactions ISO RGD:1349867 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of GPM6B mRNA CTD PMID:27188386 valproic acid increases expression ISO RGD:1349867 6480464 Valproic Acid results in increased expression of GPM6B mRNA CTD PMID:23179753 , PMID:26272509 valproic acid affects expression ISO RGD:1349867 6480464 Valproic Acid affects the expression of GPM6B mRNA CTD PMID:25979313 vancomycin decreases expression EXP 6480464 Vancomycin results in decreased expression of GPM6B mRNA CTD PMID:18930951 xylitol decreases expression ISO RGD:1349867 6480464 Xylitol results in decreased expression of GPM6B mRNA CTD PMID:32275922